A 10-Day Winning Streak Has Clorox Stock Up 24%

Clorox (CLX) stock has risen for 10 consecutive trading days, gaining 24.4% over that stretch. That added about $2.6 billion to the company's market value, which now stands at about $13.3 billion. The stock closed at $109.46 on Friday, November 13, 10.5% below its 52-week high of $122.35 and 38.1% above its low of $79.26.

How The Streak Stacks Up Against The S&P 500

Returns for CLX and the S&P 500 over the streak and the periods around it, all ending Friday, November 13 and including dividends:

Is This Move About Clorox Or The Market?

The market explains little of this: the S&P 500 lost 0.2% over the same 10 sessions, including dividends, against Clorox's +24.4%. No other S&P 500 stock is currently on a winning streak of 10 days or longer. Over the past three months the stock is up 4.8%, a window that includes the streak; over the other 53 sessions of that window it was down 15.7%.

Is The Business Keeping Up With The Stock?

On the fundamentals, revenue grew 6.3% over the last twelve months, against a median of 5.4% for S&P 500 Consumer Staples stocks; its operating margin is 14.1%, versus a median of 14.9%; and the stock trades at 19.7 times trailing earnings against a median of 22.9. The read is mixed: revenue growth above the median and a multiple below the median on one side, margins below the median on the other.

If you are looking for strength with more behind it than a hot tape, our Guidance Momentum screen surfaces the names where management raised its own outlook.

One Hot Stock Is A Story. Thirty Sound Ones Are A Strategy

A streak like this earns a place on your watchlist, and it also earns a question: how much of your outcome do you want depending on one company keeping this up?

The Trefis High Quality (HQ) Portfolio answers it with breadth: roughly 30 businesses picked for consistent cash generation, strong margins, and balance-sheet strength, sized and rebalanced by rules. It has a track record of outpacing a benchmark that combines the S&P 500, the S&P MidCap 400, and the Russell 2000. Follow the story; invest in the strategy.